Myriad Genetics (NASDAQ:MYGN) is down ~20% in Friday trading following reports that UnitedHealth Group (UNH) will no longer ...

The company is scheduled to hold its third quarter 2024 earnings conference call after the market closes on Thursday November 7, 2024, and intends to provide additional information regarding its ...

Myriad Genetics said it is in talks with UnitedHealthcare to ensure that enrollees continue to have access to its GeneSight mental health medication test after the insurer changed its coverage policy.

(NASDAQ: MYGN), a leader in genetic testing and precision ... access to multi-gene panel pharmacogenetic tests, including Myriad’s GeneSight test, under its commercial and individual exchange ...

GeneSight is designed to help healthcare ... The partnership with jscreen aims to leverage Myriad's genetic testing products and jscreen's education and genetic care programs to reach a broad ...

Notes from several investment houses indicate that the insurance giant will no longer cover genetic tests for behavioral health, which includes Myriad's GeneSight, beginning Jan. 1, 2025.

(NASDAQ: NASDAQ:MYGN), a company specializing in genetic testing and precision medicine, announced its disagreement with UnitedHealthcare's recent policy update. The insurer plans to restrict coverage ...